Key Insights

Highlights

Treatment Research

2 treatments under study, led by Vmd928 100 Mg Tablet

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT03556228Phase 1/2Recruiting

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT01137162Terminated

Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors

Showing all 2 trials

Research Network

Common Treatments

  • Vmd928 100 Mg Tablet1
  • Vmd928 Tablet And Pembrolizumab 200 Mg1

Active Sponsors

  • Stanford University1
  • VM Oncology, LLC1

Top Investigators

Related Conditions

  • Head And Neck Cancers Oropharynx2
  • Head And Neck Cancers Oral Cavity2
  • Head And Neck Cancers2
  • Head And Neck Cancers Nasopharynx2
  • Head And Neck Cancers Trachea2

Activity Timeline